GERALDINE HENWOOD Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GERALDINE HENWOOD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GERALDINE HENWOOD. GERALDINE HENWOOD is a Director in ALKERMES INC ($ALKS) and a Director in TETRAPHASE PHARMACEUTICALS INC ($TTPH) and an Chief Executive Officer in Recro Pharma, Inc. ($REPH) and a Director in Recro Pharma, Inc. ($REPH) and a President and CEO in Recro Pharma, Inc. ($REPH) and a President and CEO in Baudax Bio, Inc. ($BXRX).
Address: 88 SIDNEY STREET CAMBRIDGE 02139 MA
Companies in which GERALDINE HENWOOD is an Insider
ALKERMES INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of GERALDINE HENWOOD: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Oct 08 2009
$ALKS Market Capitalization: $8.27B
$ALKS Previous Close: $54.77
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Baudax Bio, Inc.
Industry: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
Position of GERALDINE HENWOOD: President and CEO
Holdings: 356,307 shares
Latest Transaction: May 10 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Recro Pharma, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of GERALDINE HENWOOD: Chief Executive Officer, Director, President and CEO
Holdings: 226,574 shares
Current Value: $1,823,921
Latest Transaction: Apr 22 2021
$REPH Market Capitalization: $98.40M
$REPH Previous Close: $8.05
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
TETRAPHASE PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of GERALDINE HENWOOD: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jun 11 2019
$TTPH Market Capitalization: $155.73M
$TTPH Previous Close: $4.18
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of GERALDINE HENWOOD
Sentiment: All, ALKS, BXRX, REPH, TTPH
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10 2021 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Buy | P | 0.83 | 6,000 | 4,992 | 356,307 | 350.3 K to 356.3 K (+1.71 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Grant | A | 0.00 | 26,923 | 0 | 226,574 | 199.7 K to 226.6 K (+13.49 %) |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Payment of Exercise | F | 3.03 | 6,816 | 20,652 | 199,651 | 206.5 K to 199.7 K (-3.30 %) |